The use of omalizumab for treatment‐refractory chronic spontaneous urticaria in a West Australian outpatient cohort

Abstract There is a lack of real‐world data on the use of omalizumab in treatment‐refractory chronic spontaneous urticaria (CSU). A single‐centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment‐refractory CSU. The overall response rate of 67% is comparable with that reported in the literature. Disease control and sustained remission can be achieved with omalizumab, even in patients with treatment‐resistant CSU.